Signaturefd, LLC Acadia Pharmaceuticals Inc Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Signaturefd, LLC holds 404 shares of ACAD stock, worth $6,896. This represents 0.0% of its overall portfolio holdings.

Number of Shares

404

Previous 404 -0.0%

Holding current value

$6,896

Previous $6,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	BUY	$14.62 - $18.42 $5,570 - $7,018	381 Added 1656.52%	404 $6,000
Q1 2024 May 03, 2024	SELL	$17.79 - $30.86 $480 - $833	-27 Reduced 54.0%	23 $0
Q4 2023 Jan 31, 2024	BUY	$20.78 - $31.77 $166 - $254	8 Added 19.05%	50 $1,000
Q2 2023 Aug 01, 2023	BUY	$17.8 - $25.65 $747 - $1,077	42 New	42 $1,000
Q3 2022 Nov 08, 2022	SELL	$14.11 - $18.27 $973 - $1,260	-69 Reduced 77.53%	20 $0
Q2 2022 Aug 10, 2022	SELL	$13.01 - $27.22 $39 - $81	-3 Reduced 3.26%	89 $1,000
Q1 2022 May 02, 2022	SELL	$20.94 - $27.5 $167 - $220	-8 Reduced 8.0%	92 $2,000
Q4 2021 Jan 25, 2022	BUY	$16.79 - $27.09 $1,679 - $2,709	100 New	100 $2,000
Q3 2021 Oct 28, 2021	SELL	$15.78 - $24.77 $6,627 - $10,403	-420 Closed	0 $0
Q2 2021 Jul 26, 2021	BUY	$19.4 - $27.42 $5,160 - $7,293	266 Added 172.73%	420 $10,000
Q1 2021 Apr 30, 2021	BUY	$25.02 - $54.99 $2,451 - $5,389	98 Added 175.0%	154 $4,000
Q4 2020 Feb 11, 2021	BUY	$41.04 - $56.79 $2,298 - $3,180	56 New	56 $3,000
Q3 2020 Nov 03, 2020	SELL	$36.42 - $57.0 $1,529 - $2,394	-42 Closed	0 $0
Q2 2020 Jul 30, 2020	BUY	$39.26 - $52.73 $1,648 - $2,214	42 New	42 $2,000

Others Institutions Holding ACAD

# of Institutions

279

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account